GAVI Board Teleconference
26 May 2000
Summary of Discussion
Agenda for June Board meeting
Waslander urged that discussion in the context
of R&D; consider issues relating to technology transfer and capacity
building in countries. These issues will be included in the R&D;
Task Force Terms of Reference, and will be further explored at Partners’
and Board meeting in November.
Shodu suggested discussion of African regional working
group of GAVI, arising out of recommendations at April meeting in
Abidjan. Issue to be discussed during agenda item on governance,
with summary report of meeting included in documents.
Board members endorsed the inclusion of an ‘in camera’
session as a precedent for all future GAVI board meetings.
Agenda was approved by the Board.
Endorsement of Jacques-François
Martin as Executive Director or President of the Vaccine Fund for
Kane outlined the procedure followed in the
nomination and recruitment of J.F. Martin by the interim Board of
the Vaccine Fund. Kane requested endorsement from the GAVI Board,
for a 2 year appointment, with review after 1 year.
Job description is attached.
Waslander stressed that, while the Netherlands does
not necessarily have objections to the choice of Mr Martin, the
process should have been more transparent. Future procedure to be
Board members endorsed the choice of Mr Martin.
Governance of GAVI.
Bergevin summarized the discussion between
bilateral organizations during the WHA: while it was agreed that
the GAVI board needs to remain small, there is strong desire that
the Board increases its OECD representation to 3 (Netherlands will
be regarded as OECD representative, not technical agency). To maintain
balance, an OECD increase would require an increase in developing
country representation to 3. It was decided to hold this discussion
during the ‘in camera’ session in Oslo.
Waslander urged more clarity about the roles, liabilities
and responsibilities of the GAVI Board. He informed the Board that
the government of the Netherlands requires more clarity regarding
the decision-making process especially between GAVI and the Vaccine
Alnwick concerned about the use of the word ‘governance’
in describing GAVI, which is not a legal entity but a loose alliance
of members with common objectives.
Kane described two clear roles for the GAVI board
to define policy, for which legality is not a necessity; and to
define use of Fund resources, where there is more need for legality.
document (Word document approx. 45kb) will be revised
and redistributed by Monday June 5, based on discussion and further
comments in writing, received by Wednesday 31st May.
Review of country proposals
Board members are invited to Geneva on 13-14 July
to participate in the proposal review process. The independent expert
panel will have reviewed the proposals received by 1 July, and discussed
their recommendations with the GAVI Working Group on 12 July.
Board members to inform the Secretariat of their
Return to GAVI Board